The R&D numbers for the top 10 biotechs may only amount to a fraction of what you'll find in Big Pharma. But unlike the giants, which are trying to keep a lid on multibillion-dollar budgets, you'll find a much faster crowd when you turn your gaze to the biotechs.
The economist Edward Fiedler famously said "He who lives by the crystal ball soon learns to eat ground glass," a statement to whose veracity I can readily attest having written widely on the potential of genomics during my tenure on Wall Street. Read the feature >>
Oxford University is marshaling money and scientists to explore massive datasets to uncover knowledge about diseases and treatments.
A couple of months after moving its experimental dengue vaccine into the second phase of a mid-stage study, Fort Collins, CO-based Inviragen has been snapped up by Takeda in a $250 million deal.
Kala Pharmaceuticals is developing a novel way to get drugs into the eye, and the company notched some positive results in preclinical studies, finding that its platform led to higher drug concentration for a retinal treatment.
It's the start of what locals hope will be a continued migration of smaller companies to the Alderley campus to fill the void of AZ's massive exit from the area.
Despite a major backlash in the industry, GSK has agreed to open up the data vault to investigators who intend to publish their findings, accelerating a move in the industry to provide greater transparency to the public. But the pharma giant's "independent experts" selected to run the program include at least two people with close ties to GSK.
The company, which includes Genentech legend Art Levinson on its board, has been engaged in basic scientific research for the past 5 years, with a special focus on cardio/metabolic work.
The FDA has fueled a pharmaceutical arms race in the painkiller market with the agency's decision last month to bar the sale and production of generic OxyContin, which has become one of the most widely abused opioids among Americans.
The hormone adrenomedullin is secreted by the fetus during pregnancy and appears to keep pregnant women from developing preeclampsia. And they believe it could become an effective biomarker to help pinpoint patients more likely to develop the dangerous condition.